These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32532922)

  • 1. Loss of ZIP facilitates JAK2-STAT3 activation in tamoxifen-resistant breast cancer.
    Zhu N; Zhang J; Du Y; Qin X; Miao R; Nan J; Chen X; Sun J; Zhao R; Zhang X; Shi L; Li X; Lin Y; Wei W; Mao A; Zhang Z; Stark GR; Wang Y; Yang J
    Proc Natl Acad Sci U S A; 2020 Jun; 117(26):15047-15054. PubMed ID: 32532922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ZIP restores estrogen receptor expression and response to Tamoxifen in estrogen receptor negative tumors.
    Zhu N; Zhang J; Qin X; Miao R; Du Y; Yang J
    Biochem Biophys Res Commun; 2016 Nov; 480(4):570-573. PubMed ID: 27793668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of metastatic potential by TrkB via activation of IL6/JAK2/STAT3 and PI3K/AKT signaling in breast cancer.
    Kim MS; Lee WS; Jeong J; Kim SJ; Jin W
    Oncotarget; 2015 Nov; 6(37):40158-71. PubMed ID: 26515594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3.
    Ishii Y; Waxman S; Germain D
    Cancer Res; 2008 Feb; 68(3):852-60. PubMed ID: 18245487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SIRT4 enhances the sensitivity of ER-positive breast cancer to tamoxifen by inhibiting the IL-6/STAT3 signal pathway.
    Xing J; Li J; Fu L; Gai J; Guan J; Li Q
    Cancer Med; 2019 Nov; 8(16):7086-7097. PubMed ID: 31573734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
    Raha P; Thomas S; Thurn KT; Park J; Munster PN
    Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An azaspirane derivative suppresses growth and induces apoptosis of ER-positive and ER-negative breast cancer cells through the modulation of JAK2/STAT3 signaling pathway.
    Sulaiman NB; Mohan CD; Basappa S; Pandey V; Rangappa S; Bharathkumar H; Kumar AP; Lobie PE; Rangappa KS
    Int J Oncol; 2016 Sep; 49(3):1221-9. PubMed ID: 27500741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STAT3-RANTES autocrine signaling is essential for tamoxifen resistance in human breast cancer cells.
    Yi EH; Lee CS; Lee JK; Lee YJ; Shin MK; Cho CH; Kang KW; Lee JW; Han W; Noh DY; Kim YN; Cho IH; Ye SK
    Mol Cancer Res; 2013 Jan; 11(1):31-42. PubMed ID: 23074171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
    Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
    J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
    Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
    Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells.
    Behera R; Kumar V; Lohite K; Karnik S; Kundu GC
    Carcinogenesis; 2010 Feb; 31(2):192-200. PubMed ID: 19926637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo.
    Cheng S; Castillo V; Welty M; Alvarado M; Eliaz I; Temm CJ; Sandusky GE; Sliva D
    BMC Complement Altern Med; 2017 Feb; 17(1):115. PubMed ID: 28209156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.
    Jhaveri K; Teplinsky E; Silvera D; Valeta-Magara A; Arju R; Giashuddin S; Sarfraz Y; Alexander M; Darvishian F; Levine PH; Hashmi S; Zolfaghari L; Hoffman HJ; Singh B; Goldberg JD; Hochman T; Formenti S; Esteva FJ; Moran MS; Schneider RJ
    Clin Breast Cancer; 2016 Apr; 16(2):113-22.e1. PubMed ID: 26774497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen.
    Morrissey JJ; Raney S
    Cell Biol Int; 1998; 22(6):413-9. PubMed ID: 10328849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen attenuates reactive astrocyte-induced brain metastasis and drug resistance through the IL-6/STAT3 signaling pathway.
    Xu Y; Zhu Y; Yue Y; Pu S; Wu J; Lv Y; Du D
    Acta Biochim Biophys Sin (Shanghai); 2020 Dec; 52(12):1299-1305. PubMed ID: 33355355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic interaction between ER and HMGB2 identifies DDX18 as a novel driver of endocrine resistance in breast cancer cells.
    Redmond AM; Byrne C; Bane FT; Brown GD; Tibbitts P; O'Brien K; Hill AD; Carroll JS; Young LS
    Oncogene; 2015 Jul; 34(29):3871-80. PubMed ID: 25284587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer.
    Law EK; Sieuwerts AM; LaPara K; Leonard B; Starrett GJ; Molan AM; Temiz NA; Vogel RI; Meijer-van Gelder ME; Sweep FC; Span PN; Foekens JA; Martens JW; Yee D; Harris RS
    Sci Adv; 2016 Oct; 2(10):e1601737. PubMed ID: 27730215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer.
    Mishra RR; Belder N; Ansari SA; Kayhan M; Bal H; Raza U; Ersan PG; Tokat ÜM; Eyüpoğlu E; Saatci Ö; Jandaghi P; Wiemann S; Üner A; Cekic C; Riazalhosseini Y; Şahin Ö
    Clin Cancer Res; 2018 Apr; 24(8):1987-2001. PubMed ID: 29386221
    [No Abstract]   [Full Text] [Related]  

  • 19. Tamoxifen inhibits ER-negative breast cancer cell invasion and metastasis by accelerating Twist1 degradation.
    Ma G; He J; Yu Y; Xu Y; Yu X; Martinez J; Lonard DM; Xu J
    Int J Biol Sci; 2015; 11(5):618-28. PubMed ID: 25892968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance.
    Cui Y; Parra I; Zhang M; Hilsenbeck SG; Tsimelzon A; Furukawa T; Horii A; Zhang ZY; Nicholson RI; Fuqua SA
    Cancer Res; 2006 Jun; 66(11):5950-9. PubMed ID: 16740736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.